{"pub": "marketwatch", "url": "https://marketwatch.com/articles/mallinckrodt-stock-biovectra-52-week-low-bond-opioid-litigation-51568206811", "downloaded_at": "2019-09-11 13:50:08.467538+00:00", "title": "Mallinckrodt Stock Price Nearly Doubles, but Is Still Near Historic Lows", "language": "en", "text": "The announced $250 million sale of a subsidiary sent shares of the troubled drugmaker Mallinckrodt up 84.8% on Tuesday, but the stock remains close to the bottom of its 52-week range.\n\nThe sale of Mallinckrodt\u2019s contract development and manufacturing organization, BioVectra, continued a roller-coaster month for the stock (ticker: MNK). Shares fell 38.6% on Sept. 6, following a Bloomberg report that the company had hired restructuring advisors, and then rose 17.6% the next day after the company reached settlements to get out...", "description": "The sale of its BioVectra subsidiary, announced Tuesday, gives the company a bit of a financial backstop. Mallinckrodt\u2019s piggy bank is running dangerously low; the company drew down the last $95 million of its revolving credit facility in late August.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-DF172_MNK091_OR_20190911085457.jpg", "published_at": "2019-09-11"}